Close Menu

Pacific Biosciences

Pacific Biosciences nearly doubled its product and services revenue due to sales of its Sequel instrument.

The GenomeWeb Index rose more than 6 percent in January, outperforming the Dow, Nasdaq, and Nasdaq Biotechnology Index.

It was a rough year for biotech stocks — the Nasdaq Biotech Index fell 22 percent even as the Dow gained 13 percent and the Nasdaq gained 8 percent.

The GenomeWeb Index stayed relatively flat in November, underperforming the Dow and Nasdaq for a second month in a row.

Roche said the timeline to launch a diagnostic system and assays based on PacBio's technology would be too long; instead, it will focus on commercializing Genia's technology.

The two companies struck a $75 million deal in 2013 to launch a sequencing system and assays for the diagnostic market. 

The GenomeWeb Index, which fell nearly 9 percent in October, rebounded to a 1 percent gain in November, but still underperformed the Dow and Nasdaq.

PacBio released an upgrade to its Sequel system last month that improves loading efficiency, which has increased average throughput and read length. 

PacBio's product revenues increased due to sales of its Sequel system. The company also alleged that Oxford Nanopore's products infringe on a patent it holds. 

This Week in Nature

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Pages

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.